Although the response rate for BRCA1-mutated prostate cancer to PARP inhibitors is lower (around 30%) compared to BRCA2, there is still a meaningful chance of patient benefit. In the absence of better biomarkers, the presence of the mutation alone is sufficient rationale to offer the treatment.
NCCN guidelines recommend genetic testing for a large portion of men with prostate cancer, but there are too few genetic counselors to meet demand. This systemic bottleneck forces oncologists and urologists to manage pre-test consenting and test ordering, referring only mutation-positive cases for specialized post-test counseling.
The field is moving away from distressing terms like 'castration-sensitive/resistant' toward a more precise, patient-friendly nomenclature. The new terms—APM-Naive (APMN), APM-Sensitive (APMS), and APM-Resistant (APMR)—better reflect a patient's treatment history within the modern therapeutic landscape.
While many clinical trials haven't officially counted PSMA-PET only disease as metastatic, clinicians have latitude. If a PSMA-PET scan reveals aggressive, multifocal disease, especially with a rapidly rising PSA, it should be treated as incurable metastatic cancer, justifying the initiation of systemic therapy.
Despite theoretical differences in potency or PARP1 specificity, all approved PARP inhibitors demonstrate comparable clinical toxicity profiles. Oncologists should counsel patients on a consistent class effect of myelosuppression, primarily grade 3 anemia requiring transfusion in about 25-33% of patients, regardless of the specific agent.
In prostate cancer, BRCA2 mutations typically involve complete gene loss, making them a significant oncogenic event. In contrast, BRCA1 mutations are often "passenger" mutations without complete loss of function, leading to reduced benefit from PARP inhibitors. This differs from breast and ovarian cancers, where both are highly significant.
For a newly diagnosed metastatic prostate cancer patient, an effective strategy is to initiate ADT alone while immediately ordering NGS testing. Waiting a few weeks for the genetic results before adding an ARPI allows for a more informed treatment choice, such as selecting a PARP inhibitor combination for a patient with a BRCA2 mutation.
LOH (Loss of Heterozygosity) scores offer a functional assessment of a tumor's DNA repair capability. They are computationally derived to detect a 'scar' of characteristic genomic changes, like copy number alterations, that accumulate when a tumor cannot repair DNA double-strand breaks, going beyond single-gene mutation analysis.
Early data shows that combining PARP inhibitors with radioligand therapy like lutetium-PSMA is surprisingly safe, unlike toxic combinations with chemotherapy. This promising strategy may potentiate the DNA-damaging effect of the beta-emitting radiopharmaceutical, potentially extending its benefit to a broader patient population beyond those with HR-deficient tumors.
The success of Next-Generation Sequencing (NGS) is highly dependent on sample quality. Samples older than three years have degraded DNA. Furthermore, low tumor content, common in prostate cancer bone biopsies or plasma samples, makes it difficult to reliably detect the copy number changes required for analyses like LOH scores.